(OTC Pink:GOGC)
Forward-Looking Statement
This presentation contains statements that constitute “forward-looking” statements within
the meaning of the Securities Act of 1993 and the Securities Exchange Act of 1934, as
amended by the Private Securities Litigation Reform Act of 1995. “Forward-looking”
statements contained in this presentation include the intent, belief or current expectations
of the Company and its senior management team with respect to future actions by the
Company, prospects of the Company’s operations, profits from future operations, overall
future business prospects and long-term stockholder value, as well as the assumptions
upon which such statements are based.
Investors are cautioned that any such “forward-looking” statements are not guarantees of
future performance, and that actual results may differ materially from those contemplated
by such “forward-looking” statements. Important factors currently known to management
that could cause actual results to differ materially from those contemplated by the
“forward-looking” statement in this presentation include, but are not limited to, adverse
developments involving operations of the Company’s business units, failure to meet
operating objectives or to execute the business plan, the failure to reach revenue or profit
projections and the failure to retain and hire key personnel and management. The
Company undertakes no obligation to update or revise the “forward-looking” statements
contained in this presentation to reflect changed assumptions, the occurrence of
unanticipated events, or changes to future operating results over time.
Corporate Description
Global Green, Inc. introduces Salmogenics™,
a new patented vaccine to help combat the dangerous
effects that Salmonella bacteria produce in animals
and human beings. Global Green, upon USDA
approval, plans to manufacture, market and sell
the vaccine in the poultry industry.
A unique, new patented vaccine to combat the
devastating effects of Salmonella
Why This Vaccine?
No Live
Injection
In-Ovo
Injection
Healthier
Chicken
Company Highlights



Worldwide Market Opportunity
Exclusive Rights to Two Patents Owned by N.H.I.L., a
research affiliate and majority shareholder
Only Source of New Patented Vaccine Offering:




Protection from deadly Salmonella bacteria
Healthier protein source
Potential to improve the lives of millions of people
Product Expansion Potential
Agenda

Market Opportunity

Business Strategy
Market Opportunity
Market Overview




Approximately 1.3 billion humans contract
salmonella annually, with 2-3 million resulting in
death
1 million humans in the U.S. contract salmonella
annually
40 billion chickens will benefit from the
salmonella vaccine
Salmonella is the scientific name for over 2,500
types of bacteria
The Problem is Public
“Salmonella is common in poultry, so it’s not illegal for
meat to be tainted with the pathogen.”
CBS News, August 2011
“For every laboratory-confirmed case of
Salmonella, there are at least 29 unreported cases.”
Centers for Disease Control, 2011
2010 USDA Mandate
Reduce the percentage of Salmonella
infected chicken allowed on the market
from 7% to 5%
Salmogenics has been shown in efficacy studies to help
accomplish these strict requirements
USDA Approval Progress



In last stages of testing and trials
Vaccine proven to be safe, non-toxic and causes
no harm to the animal
Studies to date conclude that Salmogenics
reduces Salmonella contamination
USDA Final Phase Status



Identify and contract USDA-approved vaccine
manufacturer
Assure requirements from the vaccine manufacturer
will meet USDA requirements
Conclusion submitted to USDA must specify:




vaccine product can be safely and standardly commercially
applied by the intended customers
claims are sustainable and reproducible when applied to
larger populations of birds
vaccine can be used in other circumstances such as a
combined treatment with other vaccines
Submit final results to USDA for approval
A
proven solution to reducing the incidence and
prevalence of Salmonella in poultry, which can
cause food poisoning in humans
Changes
the approach to the control of the
spread of an economically devastating disease
Organic Poultry Retail Market Sales
600
500
400
300
$600
Million
200
100
$161
Million
0
2005
Source: USDA
2010
Source: Dolcera Analysis
Key Growth Drivers
Poultry Vaccine Market
(Estimated to be $5.4 billion by 2015)




Growth of diseases in animals
Increasing public awareness
Technological advancements
Ability of vaccines to



Promote growth
Develop immunity against diseases
Lower animal mortality rate
Source: Global Industry Analysts
Potential Problems with Water Borne or
Spray Vaccinations with Chickens






Multiple poultry caretakers involved
Variety of vaccination equipment used
Re-use of containers = vaccine residues
Defective vaccine distribution patterns
Mixing vaccines for a complete day
Incorrect dosage of vaccine or diluent
End Result:
Added human interactions + labor costs + stress
on poultry
Advantages of In Ovo Vaccinations
Egg Yolk
Needle





Air Chamber

Earlier immunity
Uniform delivery
Fast delivery
Reduced stress
Reduced labor costs
Future products
The Global Green Advantage
is Significant
•Earlier immunity
•Uniform delivery
•Fast delivery
•Reduced stress
•Reduced labor costs
•Improved productivity
•Future products
Benefits to the Entire System
Poultry Growers
 Fast delivery
 Uniform delivery system
 Reduced labor costs for
inoculation
Chicken
 Less trauma
 Earlier immunity from
Salmonella
Humans
 Healthier protein source
Food Service Handlers
 Reduced contamination
 Healthier customers and
families
Environment
 Environmentally friendly
Incompatible with Marek’s Disease Vaccine
Other
Vaccines
Live
Bird
Non-Standardized Dosage Delivery
More Susceptible to Secondary Infections
Labor Intensive
Trauma
Increased
Cost

Less Cost, Higher Conversion, Healthier Humans
Improved Conversion
No Trauma
Salmogenics
In
Ovo
Early Immunity
Uniform Delivery
Compatible with Marek’s Disease Vaccine

Reduced
Cost
Additional Market Applications
Salmogenics = Safer Egg
Worldwide egg market =
1.3 trillion eggs per year
+
Business Strategy
Business Strategy






Complete final requirements for USDA approval
Receive final approval by USDA
Develop marketing and sales structure to
effectively convert market to Salmogenics
Establish Salmogenics as standard in the industry
Innovate through internal new product
development
Establish a leadership position in vaccine
technology with Salmogenics as the foundation
Top 10 Broiler Chicken Companies
Representing 73.7% of Chickens Processed Annually
#1
#2
#3
#4
#5
#6
#7
#8
#9
#10
Tyson Foods, Inc.
Pilgrim’s Pride Corp.
Perdue Farms, Inc.
Sanderson Farms, Inc.
Koch Foods, Inc.
Wayne Farms, LLC
Mountainaire Farms, Inc.
House of Raeford Farms, Inc.
Foster Farms, Inc.
Peco Foods, Inc.
Source:
Watt PoultryUSA Feb 2010
Global Green Evolution
and Growth Trajectory
Future
Growth and profitability
Present
Intense focus on sales
and marketing strategy is
gaining traction
Past
Developed
Salmogenics vaccine
Market Penetration Strategies




Strong and reliable regulatory approvals
Research data publications
Company and product name recognition
Advertising in leading publications
Animal production
 Food safety



Strong and experienced technical staff working
with poultry industry experts
Strong sales force focusing on top tier
customers
Major Players in Veterinary Vaccine Market
Company
Revenues from Animal Health
in 2010 ($ Bn)
Pfizer
3.575
Merck
2.900
Sanofi-Aventis
2.635
Bayer Healthcare
0.800
Virbac
0.781
Novartis
0.500
Boehringer Ingelheim
0.354
Heska Corporation
0.065
Source: Company Annual Reports
Salmogenics
Competitive Advantages





Patent positions
Improved immune system of fowl = improved
health and welfare of bird and humans
Healthier chickens = healthier protein source
Vaccine injected directly into egg = reduced
time and labor costs
End result = success of Salmogenics
Timeline








1986 – Dr. Sotomayor began research on animal health
vaccines
1995 – Technology brought to U.S.
1997 – USDA approved validation study begins
2008 – NHIL secures worldwide rights to Salmogenics
2010 – Studies as required by USDA contracted to
AHPharma
2010 – NHIL grants Salmogenics rights to Global Green
Feb 2011 – USDA Phase 4 trials began
May 2011 – Receive patent on vaccine composition
Timeline (cont’d)







Aug 2011 – Receive patent on method and composition
Oct 2011 – SEC approves Form S-1 (IPO)
Nov 2011 – Phase 4 Salmonella challenge study
completed
March 2012 – FINRA approval
March 2012 – Final report on Phase 4
Efficacy/Challenge study
April 2012 – DTC application filed
April/May - USDA-approved production facility to be
chosen
The Management Team
Name
Dr. Mehran Ghazvini, DC,NMD
Function
Chairman, CEO
and Treasurer
Dr. Rene Reed, DC, NMD
VP, Secretary
and Director
Investment Highlights





Worldwide Market Opportunity
Proprietary Patent Positions
Focused on Contributing to Human Welfare
through Technology in Vaccines and other
Nutraceuticals
Well Positioned for the Future
American-Made